KAHR Medical
PrivateLast Round
VC Round
Jan 8, 2026
Est. Valuation
$16M
Total Funding Raised
$47M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
KAHR Medical is a biotechnology company that develops dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems to treat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KAHR Medical Comparables
Compare KAHR Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QLSF Biotherapeutics | 76% | |
| ALX Oncology | 76% | |
| Gilead Sciences | 73% |
KAHR Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 8, 2026 | ||||
| Series B | Oct 14, 2025 | ||||
| Series D Extension | Nov 17, 2022 | ||||
| VC Round | Jun 16, 2021 | ||||
| VC Round | Feb 25, 2020 | ||||
Series B | Dec 15, 2015 |
KAHR Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DSC Investment | Series B |
| Korea Investment Partners | Series B |
| Mirae Asset | VC Round, Series D Extension |
| Israel Innovation Authority | Seed |
| Flerie Invest | VC Round |
| The University of Texas MD Anderson Cancer Center | VC Round |
| Consensus Business Group | Series D Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Raised $22M led by amoon-fund, Cancer Focus Fund, Peregrine Ventures, Flerie, and Flerie AB.
- Oct 14, 2025
$22M round completed.
KAHR Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about KAHR Medical's valuation, stock price, and market status.
Is KAHR a public or private company?
KAHR is a private company.
What is the current stock price of KAHR?
KAHR is a private company with no public stock price. No recent secondary market data is available.
How much is KAHR worth (valuation)?
KAHR's valuation is estimated at $16.0M based on funding round data.
Can I buy KAHR stock?
KAHR shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was KAHR's last funding round?
KAHR's most recent funding round was Series B on September 11, 2013.
Who are the main investors in KAHR?
Key investors in KAHR include DSC Investment, aMoon, Cancer Focus Fund, Pavilion Capital, Peregrine Ventures.
Will KAHR IPO soon?
No public IPO plans have been announced for KAHR.
How can I track KAHR secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor KAHR's secondary market activity and sign up for updates.